Recent chatter on X about Tonix Pharmaceuticals (TNXP) has been lively, fueled by a significant price surge of over 25% in a single day earlier this month. Many are dissecting the reasons behind this spike, with speculation centering on an anticipated FDA update regarding the company’s fibromyalgia treatment. The intensity of the discussion reflects a keen interest in whether this momentum can hold.
As the FDA decision looms, opinions on X remain divided, with some expressing optimism about potential approval and others cautioning about the challenges of execution and sales post-approval. There’s a notable focus on the company’s financial stability, with its reported cash reserves seen as a positive factor by some. The conversation continues to evolve, keeping the spotlight on TNXP as a stock to watch.
Note: This discussion summary was generated from an AI condensation of post data.
Tonix Pharmaceuticals Insider Trading Activity
Tonix Pharmaceuticals insiders have traded $TNXP stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $TNXP stock by insiders over the last 6 months:
- SETH LEDERMAN (Chief Executive Officer) purchased 4,000 shares for an estimated $86,200
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Tonix Pharmaceuticals Analyst Ratings
Wall Street analysts have issued reports on $TNXP in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Noble Capital Markets issued a "Outperform" rating on 03/20/2025
To track analyst ratings and price targets for Tonix Pharmaceuticals, check out Quiver Quantitative's $TNXP forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
